Daniel Getts

Dr. Getts is co-founder and CEO, of Myeloid Therapeutics. Prior to Myeloid, he was VP of Research at TCR2 (NASDAQ, TCRR), he was a member of the leadership team that guided the company successfully through a series B ($120M) financing and an IPO (~$80M). Dr. Getts primary duties were to lead the company's target discovery, preclinical and translational research programs. These efforts resulted in numerous patent applications, a robust pipeline and a successfully filed IND. Prior to TCR2 Dr. Getts was primary inventor, founder and Chief Scientific Officer of Cour Pharmaceuticals Development Company, a nanotechnology platform company focused on autoimmunity and inflammation. As a member of the company's leadership team he assisted in the negotiation of a number of pharmaceutical company collaborations and licenses, including with Takeda, who ultimately licensed TIMP-GLIA for $420M plus royalties.

Prior to Cour, Dr. Getts was the Director of Research & Development at Tolera Therapeutics where he was the lead immunologist responsible for advancing the company's monoclonal T cell antibody program from discovery through to Phase 3. A recipient of numerous honors and awards, including >10 issued patents and many more pending patent applications. Daniel is widely published with >45 peer-reviewed publications, with seminal publications in Nature Biotechnology, Science Translational Medicine and Nature Communications. He completed his Postdoctoral training in Stephen D. Miller's laboratory at Northwestern University. He holds a PhD in Medicine from the University of Sydney and an MBA from Western Michigan University.